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The endocannabinoid system is involved in the control of many physiological functions, including the control of emotional states.
In rodents, previous exposure to an open field increases the anxiety-like behavior in the elevated plus-maze. Anxiolytic-like
effects of pharmacological compounds that increase endocannabinoid levels have been well documented. However, these
effects are more evident in animals with high anxiety levels. Several studies have described characteristic inverted U-shaped
dose-response effects of drugs that modulate the endocannabinoid levels. However, there are no studies showing the effects of
different doses of exogenous anandamide, an endocannabinoid, in animal models of anxiety. Thus, in the present study, we
determined the dose-response effects of exogenous anandamide at doses of 0.01, 0.1, and 1.0 mg/kg in C57BL/6 mice (N = 10/
group) sequentially submitted to the open field and elevated plus-maze. Anandamide was diluted in 0.9% saline, ethyl alcohol,
Emulphor® (18:1:1) and administered ip (0.1 mL/10 g body weight); control animals received the same volume of anandamide
vehicle. Anandamide at the dose of 0.1 mg/kg (but not of 0.01 or 1 mg/kg) increased (P < 0.05) the time spent and the distance
covered in the central zone of the open field, as well as the exploration of the open arms of the elevated plus-maze. Thus,
exogenous anandamide, like pharmacological compounds that increase endocannabinoid levels, promoted a characteristic
inverted U-shaped dose-response effect in animal models of anxiety. Furthermore, anandamide (0.1 mg/kg) induced an
anxiolytic-like effect in the elevated plus-maze (P < 0.05) after exposing the animals to the open field test.
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Introduction
The discovery of the cannabinoid receptors (CB1- and
CB2-cannabinoid receptors) and their major ligands N-
arachidonylethanolamide (anandamide) and 2-arachido-
noylglycerol led to the characterization of the endocannab-
inoid system two decades ago (1-4). The endocannabi-
noid system is known to play a modulatory role in emo-
tional states such as anxiety and fear (5).
Anandamide interacts with CB1, TRPV1 and CB2 re-
ceptors (in descending order of affinity, respectively) (6).
Previous studies have described anxiolytic-like effects of a
low dose of exogenous anandamide in animals exposed to
the open field (7), or, when injected into the dorsolateral
periaqueductal gray, in the elevated plus-maze (8). A
similar effect was observed after administration of URB597,
an inhibitor of fatty acid amide hydrolase (9,10). However,
contradictory results were obtained with AM404, an inhib-
itor of anandamide re-uptake. In fact, while Bortolato et al.
(11) described an anxiolytic-like effect in the elevated plus-
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maze regarding defensive withdrawal and separation-in-
duced ultrasonic vocalizations, Bitencourt et al. (12) re-
cently reported that this effect was observed in the fear-
potentiated plus-maze test, but not in the traditional ver-
sion of the elevated plus-maze.
The present study was designed to determine the dose
x response effects of exogenous anandamide administra-
tion in adult C57BL/6 male mice sequentially submitted to
the open field and elevated plus-maze test. Indeed, there
are no studies showing the effects of different systemically
injected anandamide doses on signs indicative of anxio-
lytic-like behavior determined sequentially in two different
models and using the same animals. Previous results from
our group and others have shown that testing animals in an
open field or in a hole board immediately before the el-
evated plus-maze test significantly elevates animal activity
within this apparatus, i.e., the total number of open and
closed arm entries (13), with a consequent easier analysis
of the elevated plus-maze data.
Material and Methods
Forty male C57BL/6 mice from our own colony weigh-
ing 20-30 g and approximately 2 months old were used.
The animals were housed in groups of 4 per cage under
conditions of controlled temperature (22 ± 2°C), humidity
(65-70%), and artificial lighting (12-h light/12-h dark, lights
on at 7:00 am), with free access to rodent chow and water.
Sterilized and residue-free wood shavings were used as
animals bedding. The experiments were performed in a
different room with similar housing conditions, to which the
animals were transferred and maintained in their home
cages 7 days before the beginning of the experiments.
Animals were housed and used in accordance with the
guidelines of the Committee on Care and Use of Labora-
tory Animal Resources of the School of Veterinary Medi-
cine, University of São Paulo, Brazil.
Anandamide (N-arachidonylethanolamide) was pur-
chased from Sigma-Aldrich (USA). The compound was
made up in normal saline, ethyl alcohol, and Emulphor®,
18:1:1, and administered intraperitoneally (ip) at doses of
0.01, 0.1, and 1.0 mg/kg (0.1 mL/10 g weight) (7). Control
animals received the same volume of anandamide vehicle.
Ten minutes after treatment, the animals were first submit-
ted to an open field test and immediately after to the
elevated plus-maze test.
Both the locomotor activity in the open field and the free
exploration of the elevated plus-maze apparatus were
measured. As stated, the experiments were performed in
sequence. To minimize the influences of possible circa-
dian changes in open field and elevated plus-maze behav-
iors, control and experimental animals were alternated for
observation, being analyzed at the same time of day
(between 8:00 am and 12:00 pm). The experimental de-
vices used were washed with an alcohol-water solution
(5%) before placing the animals to obviate possible bias-
ing effects due to odor clues left by previous animals.
The open-field apparatus was described in details else-
where (14). Briefly, it consists of a round wooden arena (40
cm in diameter, 40-cm high walls) painted white and virtually
divided by software (Ethovision® version 1.9; Noldus Infor-
mation Technology, USA) into two zones: central (center +
medium) peripheral (external + thigmotaxis). The apparatus
is elevated 55 cm above the floor. For the observations, each
mouse was placed individually in the center of the apparatus
and observed for 5 min for total locomotor activity (distance
traveled in cm) and time spent (s) in locomotor activity in
each of the two open field zones. A video camera mounted
100 cm above the arena was used to collect the data that
were analyzed by an Ethovision System® software (Noldus
Information Technology) installed on an IBM-compatible
computer placed in an adjacent room.
The elevated plus-maze was made of wood, painted
white, and had two open arms (25 x 5 cm) and two
enclosed arms of the same size with 15-cm high walls. The
apparatus was elevated 55 cm above the floor. Each
mouse was placed individually in the central square of the
elevated plus-maze apparatus and allowed 5 min for free
exploration. Each mouse was observed using the same
system as described above for the open field (Ethovision
System® software; Noldus Information Technology). The
parameters recorded were: a) number of entries into the
open and closed arms and b) time spent exploring the
open and closed arms. The measures that reflect anxiety
levels in this test are the percentage of entries into open
arms versus closed arms and the percentage of time spent
in the open arms versus closed arms (14).
The animals received vehicle, 0.01, 0.1, or 1.0 mg/kg
anandamide ip in random order (N = 10/group). Each
mouse was tested in the open field and immediately after-
wards, mice previously observed in the open field were
individually tested for 5 min in the elevated plus-maze.
Bartlett’s test showed that the data obtained were
parametric. Thus, they were analyzed by one-way ANOVA
(GraphPad InStat version 3.01 for Windows) followed by
the Dunnett post hoc test. In all experiments, the probabil-
ity of P < 0.05 was taken as an indication of statistical
significance. Data are reported as means ± SEM.
Results
Anandamide at the dose of 0.1 mg/kg (but not 0.01 and
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1 mg/kg) increased the distance moved (mean ± SEM,
vehicle: 72.64 ± 7.6 cm; anandamide 0.01 mg/kg: 115.72 ±
11.1 cm; 0.1 mg/kg: 166.05 ± 21.2 cm; 1.0 mg/kg: 95.95 ±
8.2 cm) and the time spent (mean ± SEM, vehicle: 3.27 ±
0.8 s; anandamide 0.01 mg/kg: 7.49 ± 1.6 s; 0.1 mg/kg:
8.30 ± 1.8 s; 1.0 mg/kg: 3.45 ± 1.0 s) in the central zone of
the open field [F(3,36) = 9.05, P < 0.01; F(3,36) = 3.66, P <
0.05, respectively). Although a dose of 0.1 mg/kg is not
able to change the locomotion in peripheral zone of the
arena, the doses of 0.01 and 1 mg/kg, respectively, in-
creased (P < 0.05) and decreased (P < 0.01) (mean ±
SEM, vehicle: 992.55 ± 27.7 cm; anandamide 0.01 mg/kg:
1100.24 ± 31.0 cm; 0.1 mg/kg: 1045.38 ± 38.0 cm; 1.0 mg/
kg: 821.07 ± 24.6 cm) the locomotion in this zone com-
pared to control [F(3,36) = 15.45]. Interestingly, no statisti-
cal difference in total distance moved or total time spent in
movement was observed compared to control, even though
the characteristic inverted U-shape pattern was still pres-
ent (see Figure 1).
Figure 2A and B show the effects of anandamide in the
elevated plus-maze. The dose of 0.1 mg/kg (but not 0.01
and 1 mg/kg) increased both the percentage of entries
(mean ± SEM, vehicle: 22.71 ± 3.3%; anandamide 0.01
mg/kg: 22.90 ± 2.3%; 0.1 mg/kg: 34.76 ± 3.7%; 1.0 mg/kg:
23.23 ± 3.8%) [F(3,36) = 3.18, P < 0.05] and the percent-
age of time spent (mean ± SEM, vehicle: 2.88 ± 0.9%;
anandamide 0.01 mg/kg: 4.43 ± 1.0%; 0.1 mg/kg: 17.70 ±
4.1%; 1.0 mg/kg: 6.32 ± 2.7%) in the open arms [F(3,36) =
6.88, P < 0.01] compared to control. As expected, the
contrary was observed in the closed-arms of the apparatus
(data not shown). Furthermore, no differences [F(3,36 =
1.641, P = 0.197] were found in total arm entries (mean ±
SEM, vehicle: 15.2 ± 1.67; anandamide 0.01 mg/kg: 17.0 ±
Figure 2. Effects of anandamide in the elevated plus-maze test. Data are reported as mean ± SEM for N = 10 per group. A, Percent
entries into the open arms during the 5 min of the test. B, Percent time spent in the open arms during the 5 min of the test. *P < 0.05
compared to vehicle (one-way ANOVA followed by the Dunnett post hoc test).
Figure 1. Effects of anandamide on the exploration in the central,
peripheral and total area of the open field apparatus. Data are
reported as mean ± SEM for N = 10 per group. A, Time spent in
movement during the 5 min of the test. B, Distance covered
during the 5 min of the test. *P < 0.05 compared to vehicle (one-
way ANOVA followed by the Dunnett post hoc test).
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1.67; 0.1 mg/kg: 19.6 ± 2.55; 1.0 mg/kg: 14.3 ± 1.11).
Discussion
In the present study, we have demonstrated an anxio-
lytic-like response after the exogenous administration of
anandamide at the dose of 0.1 mg/kg (but not at 0.01 and
1.0 mg/kg) in both the open field and elevated plus-maze.
In agreement with these data, we observed no change in
gait or in the mean velocity in the open field (data not
shown) or in the total number of arm entries within the
elevated plus-maze (mean ± SEM described above), facts
that strongly suggest the presence of normal locomotor
activity. We observed that treatment with 0.1 mg/kg anan-
damide led to an increase in exploration mainly in the open
field central zone. This particular behavior might be an
indication of an anxiolytic-like effect induced by ananda-
mide, since it is known that rodents present a conflict
between their natural curiosity to explore novel areas
versus an aversion of open areas when first exposed to
them (15,16). The data obtained in the elevated plus-maze
agree with the anxiolytic-like effect induced by ananda-
mide (0.1 mg/kg) in the open field. We observed an in-
crease in both percent time spent and the percent entries
into the open arms. Both the increased percentage of
entries and of time spent exploring the open arms together
with the absence of changes in the total number of arm
entries are considered to be good indicators of anxiolytic-
like effects in this model (17). Therefore, our data corrobo-
rate with some recent reports that have shown the anxio-
lytic-like effects of anandamide in different models of anxi-
ety, such as the Vogel conflict test (18), elevated plus-
maze (19), and light/dark box test (20). Furthermore, some
reports have shown the same anxiolytic-like properties of
compounds that alter endocannabinoid signaling, such as
AM404 (an anandamide transport inhibitor) (8) and URB597
(an inhibitor of anandamide hydrolysis) (9).
Additionally, in the present study, a characteristic in-
verted U-shaped dose-response curve for anandamide
was observed in both the open field and elevated plus-
maze. Other studies have shown the anxiolytic-like effect
induced by anandamide with a characteristic inverted U-
shaped pattern curve after its administration, in addition to
other compounds that alter endocannabinoid signaling in
rodents (8-11). Using a dose-response protocol, Moreira
et al. (8) showed that intra-dorsolateral periaqueductal
injection of anandamide produced an inverted U-shape
curve and an anxiolytic-like effect in the elevated plus-
maze (8). More recently Scherma et al. (20) showed that
anandamide systemically injected produced an anxiolytic-
like effect in the light/dark box test at a dose (0.3 mg/kg)
closely similar to that used in our study.
This characteristic inverted U-shape pattern is the re-
sult of the biphasic effects observed after low and high
doses of (endo)cannabinoids. Low doses are reported to
be anxiolytic, whereas high doses are reported to be
anxiogenic (5). In the past, it was difficult to explain these
findings; however, it has been recently proposed that the
opposite effects produced by low and high doses of these
compounds might be due to their ability to interact with
different receptors (6). Recently, Rubino et al. (19) demon-
strated that the anxiolytic-like effect of a low anandamide
dose was reversed by administration of the specific CB1
receptor antagonist AM251, whereas the anxiogenic-like
effect was inhibited by pretreatment with capsazepine, a
TRPV1 (transient receptor potential vanilloid type 1) re-
ceptor antagonist. The authors suggested that the anxio-
lytic effect evoked by anandamide might be due to the
interaction with the CB1 cannabinoid receptor, whereas
vanilloid receptors seem to be involved in the anxiogenic
action of anandamide (19). Therefore, the anandamide-
induced inverted U-shape pattern might be based on the
fact that the intrinsic efficacy of anandamide on TRPV1 is
relatively low compared to that observed on the CB1 re-
ceptor (6).
Moreover, a recent report by Bitencourt et al. (12)
showed an anxiolytic-like effect of AM404 and cannabidiol
in a model of fear-potentiated elevated plus-maze. This
study suggests that these compounds exert distinct effects
depending on the emotional state of the individual, thus
representing an original class of anxiolytic drugs. This
hypothesis is supported by the observation of oscillations
in endocannabinoid tonus during stressful situations (12).
Interestingly, in our work, mice were tested in the elevated
plus-maze immediately after the stress of being placed in
the open field arena. Although the behavioral outcomes of
anandamide in the open field were not very different, in the
elevated plus-maze the effect of 0.1 mg/kg was exceed-
ingly evident. Differences in animal response to fear of
novelty (open field) versus fear of open and elevated areas
(elevated plus-maze) might account for the more promi-
nent effect of anandamide in the latter apparatus. Indeed,
the elevated plus-maze is known to be more stressful than
the open field (15). These assumptions agree with this
recent reported data (12).
This research showed for the first time a dose-re-
sponse effect for the anxiolytic-like effects of anandamide
injected systemically. Moreover, our results corroborated
recent data (12) that showed the relevance of the emo-
tional state of the individual for the anxiolytic-like effects of
the (endo)cannabinoids, such as anandamide.
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